Dr Roger Askew

Biography

Roger joined the Ozgene team in May 2015 as Ozgene's Principal Scientist North America. He is based in Boston, MA. Roger comes to us with twenty years of industry experience developing and phenotyping genetically engineered models (GEMs) in collaborative support of the Therapeutic Areas (TAs) at three pharmaceutical companies. Roger received his PhD from Wesleyan University, Dept of Molecular Biology and Biochemistry and spent his post-doctoral days at the University of Cincinnati Medical School in the laboratories or Drs Jerry Lingrel and Thomas Doetschman where he developed the gene-targeted “Tag-and-Echage" strategy for knocking in subtle mutations, including point mutations, into the mouse genome.

Research Interest

Roger’s Pharma career started at Wyeth Pharmaceuticals, where he established the gene targeting core and managed the Molecular Genetics Department supporting all Wyeth TAs. Next Roger joined Merck & co., where he managed outsourced GEM development and phenotyping supporting the Diabetes, and Bone & Endocrinology pipelines. Most recently, he established Biogen’s GEM Center supporting Neurology, Immunology, and Tissue Injury and Fibrosis TAs. Roger enthusiastically engages with scientists from all areas. Please feel free to contact him to plan a hike in the high Sierras or to brainstorm genetically engineered models and the characterization/phenotyping of your GEMs of interest.